The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity

The EMPA-REG OUTCOME study revealed that a sodium-glucose cotransporter 2 (SGLT2) inhibitor, empagliflozin, can remarkably reduce cardiovascular (CV) mortality and heart failure in patients with high-risk type 2 diabetes. Recently, the CANVAS program also showed that canagliflozin, another SGLT2 inh...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Front Endocrinol (Lausanne)
Hlavní autoři: Wan, Ningning, Rahman, Asadur, Hitomi, Hirofumi, Nishiyama, Akira
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2018
Témata:
Endocrinology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6070601/
https://ncbi.nlm.nih.gov/pubmed/30093883
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2018.00421
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky